Anzeige
❌
Mehr »
Sonntag, 22.11.2026 - Börsentäglich über 12.000 News
Zufall oder Strategie? Copper One zündet die nächste Stufe seiner Kupfer-Offensive!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
NF

WKN: A2P5N7 | ISIN: FI4000330972 | Ticker: 4YL
Frankfurt
20.11.26 | 09:05
0,720 Euro
-2,70 % -0,020
Branche
Nanotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
NANOFORM FINLAND OYJ Chart 1 Jahr
5-Tage-Chart
NANOFORM FINLAND OYJ 5-Tage-Chart
RealtimeGeldBriefZeit
0,6860,75319:02

Aktuelle News zur NANOFORM FINLAND Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoNanoform Q3 2026 slides: expenses down 35%, GMP readiness nears1
DoEarnings Call zu Nanoform im 3. Quartal 2026: Sinkende Betriebskosten und Pipeline-Fortschritte im Fokus3
DoNanoform Finland Oyj Q3 Loss Declines1
DoNanoform Finland Oyj: Nanoform Q3 2026 - Agreement signed with global CDMO around Nanoform's Ultra-High-Concentration Biologics technology, targeted readiness for GMP supply during 2H27194Nanoform Finland Plc | Company Release | November 19, 2026 at 08:10:00 EET Agreement signed with global CDMO around Nanoform's Ultra-High-Concentration Biologics technology, targeted readiness for GMP...
► Artikel lesen
20.08.Earnings Call: Nanoform reduziert Cash-Burn in Q2 2026 und erzielt regulatorische Fortschritte1
20.08.Nanoform Q2 2026 slides: cash burn drops 57% as GMP projects rise1
20.08.Nanoform Finland Oyj Q2 Loss Declines3
NANOFORM FINLAND Aktie jetzt für 0€ handeln
20.08.Nanoform steigert Umsatz um 16 % und verringert Quartalsverlust2
20.08.Nanoform Finland Oyj: Nanoform Q2 2026 - Positive feedback from scientific advice meeting in the UK, significantly improved cash flow and discussions with CDMOs on sterile GMP for our Biologics technology initiated766Nanoform Finland Plc | Company Release | August 20, 2026 at 08:10:00 EEST Nanoenzalutamide project continues with the communicated multitrack strategy supported by all partners. After a positive scientific...
► Artikel lesen
05.08.Nanoform Finland Oyj: Inside information: Positive Feedback from UK MHRA Scientific Advice Meeting regarding Nanoenzalutamide559Nanoform Finland Plc | Inside Information | August 05, 2026 at 12:00:00 EEST Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, announced today that it...
► Artikel lesen
19.05.Nanoform Finland Oyj: Nanoform Q1 2026 report - Record first quarter revenue, income and gross margin, first exclusivity deal signed around our Biologics technology1.072Nanoform Finland Plc | Company Release | May 19, 2026 at 08:10:00 EEST Record first quarter revenue, income and gross margin. Revenue grew by 45%, gross margin reached 94% and operating costs fell by...
► Artikel lesen
12.05.Nanoform Finland Oyj: Inside information: Nanoform Signs First Exclusivity Agreement for Ultra-High Concentration Subcutaneous Delivery953Nanoform Finland Plc | Inside Information | May 12, 2026 at 08:00:00 EEST Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced that it has...
► Artikel lesen
21.04.Nanoform Finland Oyj: Resolutions of Nanoform Finland Plc's Annual General Meeting on April 21, 2026754Nanoform Finland Plc | Company Release | April 21, 2026 at 12:20:00 EEST Nanoform Finland Plc (the "Company" or "Nanoform") held its Annual General Meeting for 2026 on April 21, 2026 at the Company's...
► Artikel lesen
02.03.Nanoform Finland Oyj: The Board of Directors of Nanoform Finland Plc decided on issue of stock options under an option program open to all employees1.107Nanoform Finland Plc | Company Release | March 02, 2026 at 08:10:00 EET Helsinki, Finland - The Annual General Meeting of Nanoform Finland Plc ("Nanoform") has on 15 April 2025 authorized the company's...
► Artikel lesen
26.02.Nanoform Finland Oyj: Nanoform Q4 & FY2025 report - Next: the submission of a marketing authorization application for Nanoenzalutamide in Europe1.034Nanoform Finland Plc | Company Release | February 26, 2026 at 08:10:00 EET Product kernel strategy continues to gain traction. Nanoenzalutamide: pivotal human fed and fasted study concluded, three more...
► Artikel lesen
07.01.Nanoform Finland Oyj: Inside information: Nanoform starts change negotiations as part of announced new midterm business targets for 20301.063Nanoform Finland Plc | Inside Information | January 07, 2026 at 08:05:00 EET Helsinki, Finland - Nanoform Finland Plc ("Nanoform") starts change negotiations in accordance with the Act on Cooperation....
► Artikel lesen
16.12.25Nanoform Finland Oyj: Inside information: Nanoform announces new midterm business targets for 20301.884Nanoform Finland Plc | Inside Information | December 16, 2025 at 07:00:00 EET Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced new midterm...
► Artikel lesen
17 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1